Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients.

Lung cancer (Amsterdam, Netherlands) - 1 Nov 2006

Han Sae-Won, Kim Tae-You, Lee Kyung-Hun, Hwang Pil Gyu, Jeon Yoon Kyung, Oh Do-Youn, Lee Se-Hoon, Kim Dong-Wan, Im Seock-Ah, Chung Doo Hyun, Heo Dae Seog, Bang Yung-Jue

Abstract excerpt

BACKGROUND: Clinical predictors including Asian, female, adenocarcinoma and never-smoker and epidermal growth factor mutation are associated with gefitinib responsiveness in non-small-cell lung cancer. Direct comparison between clinical predictors and EGFR mutation for their predictive power has not been reported. PATIENTS AND METHODS: For 120 Korean NSCLC patients treated with gefitinib, we have analyzed EGFR...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Aged

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Aged, 80 and over

Share to Asian People

Share to Carcinoma, Squamous Cell

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Mutation

Source

Identifiers

PMID: 16956694
DOI: 10.1016/j.lungcan.2006.07.007

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients.PMID 16956694Read ↗

Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With GefitinibSemantic proximity Read ↗

The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.Semantic proximity Read ↗

Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer.Semantic proximity Read ↗

Non-small cell lung cancer - genetic predictorsSemantic proximity Read ↗

The characterization of gefitinib sensitivity and adverse events in patients with non-small cell lung cancer.Semantic proximity Read ↗

Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib-treated patients with lung adenocarcinoma.Semantic proximity Read ↗

Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.Semantic proximity Read ↗

The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers.Semantic proximity Read ↗

EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients.Semantic proximity Read ↗

Sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in males, smokers, and non-adenocarcinoma lung cancer in patients with EGFR mutations.Semantic proximity Read ↗

Clinical outcomes of advanced non-small cell lung cancer patients screened for epidermal growth factor receptor gene mutations.Semantic proximity Read ↗

EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.